Literature DB >> 20155388

New techniques for drug delivery to the posterior eye segment.

Esther Eljarrat-Binstock1, Jacob Pe'er, Abraham J Domb.   

Abstract

Ocular drug delivery has become an increasingly important field of research especially when treating posterior segment diseases of the eye, such as age-related macular degeneration, diabetic retinopathy, posterior uveitis and retinitis. These diseases are the leading causes of vision loss in developed countries which require repeated long-term administration of therapeutic agents. New drugs for the medication of the posterior ocular segment have emerged, but most drugs are delivered by repeated intravitreal injections associated with ocular complications. Advances in ocular drug delivery system research are expected to provide new tools for the treatment of the posterior segment diseases, providing improved drug penetration, prolonged action, higher efficacy, improved safety and less invasive administration, resulting in higher patient compliance. This review provides an insight into the recent progress and trends in ocular drug delivery systems for treating posterior eye segment diseases, with an emphasis on transscleral iontophoresis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155388     DOI: 10.1007/s11095-009-0042-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  122 in total

Review 1.  Enhancement of ocular drug penetration.

Authors:  H Sasaki; K Yamamura; T Mukai; K Nishida; J Nakamura; M Nakashima; M Ichikawa
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1999       Impact factor: 4.889

2.  Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.

Authors:  Claudio Bucolo; Adriana Maltese; Francesco Maugeri; Barbara Busà; Giovanni Puglisi; Rosario Pignatello
Journal:  J Pharm Pharmacol       Date:  2004-07       Impact factor: 3.765

Review 3.  Industrial perspective in ocular drug delivery.

Authors:  Yusuf Ali; Kari Lehmussaari
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

4.  Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates.

Authors:  G A Peyman; M Conway; B Khoobehi; K Soike
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

5.  Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles.

Authors:  C Losa; P Calvo; E Castro; J L Vila-Jato; M J Alonso
Journal:  J Pharm Pharmacol       Date:  1991-08       Impact factor: 3.765

6.  Ocular toxicity of iontophoretic foscarnet in rabbits.

Authors:  M O Yoshizumi; D A Lee; D A Sarraf; R A Equi; W Verdon
Journal:  J Ocul Pharmacol Ther       Date:  1995       Impact factor: 2.671

Review 7.  Ocular delivery using poly(ortho esters).

Authors:  Jorge Heller
Journal:  Adv Drug Deliv Rev       Date:  2005-11-08       Impact factor: 15.470

8.  Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe.

Authors:  Joseph Frucht-Pery; Hadas Mechoulam; Charalambos S Siganos; Pnina Ever-Hadani; Mervyn Shapiro; Abraham Domb
Journal:  Exp Eye Res       Date:  2004-03       Impact factor: 3.467

9.  A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit.

Authors:  P Fitzgerald; J Hadgraft; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1987-06       Impact factor: 3.765

10.  Trans-scleral iontophoresis of gentamicin.

Authors:  N L Burstein; L H Leopold; D B Bernacchi
Journal:  J Ocul Pharmacol       Date:  1985
View more
  38 in total

Review 1.  Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2011-12-14       Impact factor: 3.633

Review 2.  Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms.

Authors:  C Hernández; A Simó-Servat; P Bogdanov; R Simó
Journal:  J Endocrinol Invest       Date:  2017-03-29       Impact factor: 4.256

3.  Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration.

Authors:  Xueming Wu; Guanping Yu; Chengcai Luo; Akiko Maeda; Ning Zhang; Da Sun; Zhuxian Zhou; Anthony Puntel; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  ACS Nano       Date:  2013-12-20       Impact factor: 15.881

Review 4.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

5.  Influence of permeant lipophilicity on permeation across human sclera.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  Pharm Res       Date:  2010-08-24       Impact factor: 4.200

Review 6.  Reservoir-based drug delivery systems utilizing microtechnology.

Authors:  Cynthia L Stevenson; John T Santini; Robert Langer
Journal:  Adv Drug Deliv Rev       Date:  2012-02-21       Impact factor: 15.470

Review 7.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

Review 8.  Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

9.  Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration.

Authors:  Stacy Hu; Steven Koevary
Journal:  J Ocul Pharmacol Ther       Date:  2016-01-15       Impact factor: 2.671

Review 10.  Neuroprotection in diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.